oncology
Lung Cancer

Smoking status does not reduce immunotherapy efficacy in lung cancer

Australian research has found that contrary to some previous reports, a history of smoking does not reduce the efficacy of immune checkpoint inhibitors in people with lung cancer. Some study-level meta-analyses have suggested that never smokers with non-small cell lung cancer (NSCLC) may obtain less effect from ICIs than previous or current smokers, a finding ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic